- Home
- IRMD vs MLYS Comparison
IRMD vs MLYS Comparison
Compare IRMD & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- MLYS
- Stock Information
- Founded
- IRMD 1992
- MLYS 2019
- Country
- IRMD United States
- MLYS United States
- Employees
- IRMD N/A
- MLYS N/A
- Industry
- IRMD Medical/Dental Instruments
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- MLYS Health Care
- Exchange
- IRMD Nasdaq
- MLYS Nasdaq
- Market Cap
- IRMD 766.5M
- MLYS 526.1M
- IPO Year
- IRMD 2014
- MLYS 2023
- Fundamental
- Price
- IRMD $60.86
- MLYS $10.21
- Analyst Decision
- IRMD Strong Buy
- MLYS Strong Buy
- Analyst Count
- IRMD 1
- MLYS 2
- Target Price
- IRMD $60.00
- MLYS $30.00
- AVG Volume (30 Days)
- IRMD 36.9K
- MLYS 263.5K
- Earning Date
- IRMD 02-13-2025
- MLYS 03-20-2025
- Dividend Yield
- IRMD 0.98%
- MLYS N/A
- EPS Growth
- IRMD 13.16
- MLYS N/A
- EPS
- IRMD 1.46
- MLYS N/A
- Revenue
- IRMD $71,305,130.00
- MLYS N/A
- Revenue This Year
- IRMD $13.60
- MLYS N/A
- Revenue Next Year
- IRMD $10.46
- MLYS N/A
- P/E Ratio
- IRMD $41.82
- MLYS N/A
- Revenue Growth
- IRMD 13.23
- MLYS N/A
- 52 Week Low
- IRMD $40.18
- MLYS $8.58
- 52 Week High
- IRMD $61.25
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- IRMD 57.38
- MLYS 44.53
- Support Level
- IRMD $59.63
- MLYS $9.57
- Resistance Level
- IRMD $61.09
- MLYS $10.79
- Average True Range (ATR)
- IRMD 1.53
- MLYS 0.64
- MACD
- IRMD -0.12
- MLYS 0.11
- Stochastic Oscillator
- IRMD 63.33
- MLYS 63.98
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.